Acquired Immunodeficiency Syndrome Market Pegged for Robust Expansion by 2025

Posted by Aman Jaiswar on June 17th, 2019

Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection.

View Report -

https://www.transparencymarketresearch.com/acquired-immunodeficiency-syndrome-market.html

Globally, the number of annual deaths caused due to HIV/AIDS declined from 2.3 million in 2005 to 1.5 million in 2013, according to a report on AIDS published by the UN. For the treatment of AIDS/HIV, anti-retroviral therapy (ART) is used, which is a combination of medicines that have proved to be effective for years. Anti-retroviral therapy prevents the multiplication of human immunodeficiency virus, and thereby, reduces virus in the patient’s body, protecting the immune system. HIV regimen initially includes three anti-retroviral drugs from at least two different drug classes.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39197

If employed on time, anti-retroviral therapy prevents HIV infection from culminating into AIDS; the therapy increases the lifespan of the patient and also significantly reduces the risk of transmission of the virus. Pharmaceutical companies are focusing on research and development of novel drugs that can prove to be a long-term cure for HIV virus and can forever suppress the virus throughout the life of an individual. Thus, anticipated approval of several new drugs for treatment of AIDS in the near future is poised to propel the growth of the acquired immunodeficiency syndrome treatment market during the forecast years.

The acquired immunodeficiency syndrome treatment market can be divided into drug therapy, gene therapy, cell therapy, and others. Based on disease indication, the acquired immunodeficiency syndrome treatment market can be categorized into genetic disorders, rare cancer, rare blood disorders, autoimmune disorders, infectious diseases, and others. In terms of region, the acquired immunodeficiency syndrome treatment market can be classified into Asia Pacific (APAC), Europe, Middle East & Africa (MEA), North America (NA), and Latin America (LA).